↓ Skip to main content

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Overview of attention for article published in Clinical Epigenetics, October 2020
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
Published in
Clinical Epigenetics, October 2020
DOI 10.1186/s13148-020-00948-9
Pubmed ID
Authors

Mu-Chen Zhang, Ying Fang, Li Wang, Shu Cheng, Di Fu, Yang He, Yan Zhao, Chao-Fu Wang, Xu-Feng Jiang, Qi Song, Peng-Peng Xu, Wei-Li Zhao

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 15%
Other 3 11%
Student > Bachelor 3 11%
Student > Master 3 11%
Student > Doctoral Student 2 7%
Other 4 15%
Unknown 8 30%
Readers by discipline Count As %
Medicine and Dentistry 7 26%
Biochemistry, Genetics and Molecular Biology 6 22%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Unspecified 1 4%
Immunology and Microbiology 1 4%
Other 3 11%
Unknown 8 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2020.
All research outputs
#14,808,388
of 19,206,351 outputs
Outputs from Clinical Epigenetics
#774
of 1,051 outputs
Outputs of similar age
#274,363
of 389,489 outputs
Outputs of similar age from Clinical Epigenetics
#90
of 145 outputs
Altmetric has tracked 19,206,351 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,051 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 389,489 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 145 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.